Biomarin Pharmaceutical Inc (BMRN) insider trading
Every open-market stock purchase and sale by Biomarin Pharmaceutical Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $3.2M over the last 12 months (4 sales). No open-market buys.
- Last insider buy: Mark J Alles (Director), $314K, 3 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $3.2M (4 sales). Last close $56.77 on Jun 4, 2026.
Recent BMRN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 2, 2026 | Elizabeth M Anderson (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Willard H Dere (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Ian T Clark (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Robert J. Hombach (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Maykin Ho (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Athena Countouriotis (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Mark J Enyedy (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Timothy P Walbert (Director) | Bought (not open market) | — |
| Jun 2, 2026 | Barbara W. Bodem (Director) | Bought (not open market) | — |
| May 20, 2026 | Cristin Hubbard (C-suite exec) | Sold (not open market) | $116K |
| May 7, 2026 | Gregory R Friberg (VP) | Sold | $177K |
| Mar 18, 2026 | George Eric Davis (C-suite exec) | Sold (not open market) | $71.4K |
| Mar 17, 2026 | Alexander Hardy (CEO) | Sold (not open market) | $238K |
| Mar 17, 2026 | Brian Mueller (CFO) | Sold (not open market) | $119K |
| Mar 17, 2026 | Charles Greg Guyer (CTO) | Sold (not open market) | $94.9K |
| Mar 17, 2026 | Gregory R Friberg (VP) | Sold (not open market) | $91.3K |
| Mar 17, 2026 | Cristin Hubbard (C-suite exec) | Sold (not open market) | $69.8K |
| Mar 16, 2026 | George Eric Davis (C-suite exec) | Sold (not open market) | $420K |
| Mar 16, 2026 | George Eric Davis (C-suite exec) | Bought (not open market) | — |
| Mar 16, 2026 | Brian Mueller (CFO) | Bought (not open market) | — |
| Mar 16, 2026 | Cristin Hubbard (C-suite exec) | Bought (not open market) | — |
| Mar 16, 2026 | Brian Mueller (CFO) | Bought (not open market) | — |
| Mar 16, 2026 | George Eric Davis (C-suite exec) | Bought (not open market) | — |
| Mar 16, 2026 | Alexander Hardy (CEO) | Bought (not open market) | — |
| Mar 16, 2026 | Gregory R Friberg (VP) | Bought (not open market) | — |
Who's trading BMRN
- Elizabeth M Anderson, Director: other filings, last Jun 2, 2026
- Barbara W. Bodem, Director: other filings, last Jun 2, 2026
- Ian T Clark, Director: other filings, last Jun 2, 2026
- Athena Countouriotis, Director: other filings, last Jun 2, 2026
- Willard H Dere, Director: other filings, last Jun 2, 2026
- Mark J Enyedy, Director: other filings, last Jun 2, 2026
- Robert J. Hombach, Director: other filings, last Jun 2, 2026
- Maykin Ho, Director: other filings, last Jun 2, 2026
- Timothy P Walbert, Director: other filings, last Jun 2, 2026
- Cristin Hubbard, C-suite exec: other filings, last May 20, 2026
- Gregory R Friberg, VP: sold $559K (2 sales), last May 7, 2026
- George Eric Davis, C-suite exec: sold $1.6M (1 sale), last Mar 18, 2026
- Alexander Hardy, CEO: other filings, last Mar 17, 2026
- Charles Greg Guyer, CTO: sold $997K (1 sale), last Mar 17, 2026
- Brian Mueller, CFO: other filings, last Mar 17, 2026
Get free alerts when an insider at Biomarin Pharmaceutical Inc files a new trade →